CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Fujian Haixi Pharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Fujian Haixi Pharmaceuticals Co Ltd
Phone: +86 59187519936p:+86 59187519936 FUZHOU, FUJ  350028  China Ticker: 26372637
Business Summary
Fujian Haixi Pharmaceuticals Co Ltd is a China-based company principally engaged in the research, development, production, and sales of generic drugs and innovative drugs. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The Company mainly operates its businesses in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, General Counsel XinshanKang 54 12/1/2024 3/1/2012
Finance Director, Joint Secretary JunhuanZhang 56 10/1/2022 10/1/2021
Chief Scientific Officer, Deputy General Manager, Executive Director GuangmingChen 61 12/1/2024 5/1/2022
9 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 78,707,270 (As of 10/17/2025)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 24, 2025